You are viewing: Australia Multiomics Market analysis
Part of: Multiomics Market (Global)

The Australia Multiomics Market was valued at $47.4 Million in 2026 and projected to reach to $83.5 Million by 2031, representing a compound annual growth rate of 12.0%. Australia's multiomics market is positioned for sustained expansion driven by increasing healthcare digitalization, growing adoption of personalized medicine, and substantial government funding for genomic research initiatives.

Australia Multiomics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Multiomics Market Trends and Insights

  • Valued at $47.4 million in 2026, Australia's market is expected to expand to $83.5 million by 2031, reflecting a compound annual growth rate of 12.0%.
  • This growth trajectory underscores Australia's increasing adoption of integrated genomic, proteomic, and metabolomic technologies across research institutions, diagnostic laboratories, and clinical settings. The expansion of Australia's multiomics market is driven by rising investments in precision medicine infrastructure, growing demand for personalized healthcare solutions, and strengthening collaborations between academic centers and biotechnology firms.
  • Australia's regulatory environment and emphasis on advanced diagnostics continue to support market penetration.
  • Between 2026 and 2031, Australia is anticipated to see accelerated deployment of multiomics platforms in oncology, infectious disease, and chronic disease management, positioning the country as a key regional hub for omics-driven innovation. Australia's multiomics sector benefits from a skilled workforce, government funding initiatives, and proximity to Asia Pacific markets, creating competitive advantages for both local and international market participants seeking to establish regional operations..

Key Market Statistics

  • CAGR (2026-2031) 12.0% CAGR
  • Market Size, 2026 ~USD 47.4 Million
  • Forecast, 2031 ~USD 83.5 Million
  • Country Australia

Australia Multiomics Market Overview

Market Valuation Growth :

Australia's multiomics market is valued at $47.4 million in 2026 and is projected to reach $83.5 million by 2031, representing a robust 12% CAGR over the forecast period.

Asia Pacific Leadership Position :

Australia is emerging as a high-growth segment within the Asia Pacific healthcare landscape, leveraging advanced research infrastructure and increasing investment in precision medicine initiatives.

Technology Integration Adoption :

Australian healthcare institutions are rapidly adopting integrated genomic, proteomic, and metabolomic technologies, driving demand for comprehensive multiomics solutions across clinical and research settings.

Competitive CAGR Performance :

Australia's 12% CAGR aligns closely with the global multiomics market growth rate of 12.3%, indicating strong market maturity and alignment with international healthcare trends.

Australia Multiomics Market Dynamics

  • The country's advanced healthcare infrastructure and strong biotech ecosystem support the integration of multiomics technologies across diagnostic, therapeutic, and research applications. Key growth drivers include rising prevalence of chronic diseases, expanding clinical applications of multiomics data, and collaborative partnerships between research institutions and healthcare providers.
  • With a projected 76% market increase from 2026 to 2031, Australia is establishing itself as a significant multiomics hub within the Asia Pacific region, attracting both domestic and international investment in precision healthcare solutions..

Market Ecosystem

logo-mobile

MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina)
company logo
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Australia's multiomics market will grow from $47.4M (2026) to $83.5M (2031) at a 12.0% CAGR, outpacing many developed markets.
    • Australia's adoption of multiomics technologies is accelerating in precision oncology, infectious disease diagnostics, and personalized medicine applications.
    • Australia's regulatory framework and government support for precision health initiatives are key enablers of market expansion through 2031.
    • Australia's position as a regional innovation hub attracts international multiomics vendors and strengthens local biotechnology ecosystem development.

    Multiomics Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment SERVICES (Offering)
    Forecast Period 2026-2031
    Growth Rate CAGR of 12.3% from 2026 to 2031
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 3.19 (2026)
    Revenue Forecast (Billions) ~USD 5.7 (2031)
    Segments Covered Offering, Type, Technology, Method, Workflow, Application, End User

    Australia Multiomics Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services

    By Type

    • Assay Kits & Reagents
    • Consumables
    • Instruments & Software
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Nanopore Sequencing
    • Ngs-Based Proteomics
    • Other Consumables
    • Other Proteomics Methods
    • Other Sequencing Technologies
    • Pcr-Based Proteomics
    • Smrt Sequencing

    By Technology

    • Long-Read Sequencing
    • Nanopore Sequencing
    • Other Sequencing Technologies
    • Other Technologies
    • Proteomics
    • Sequencing
    • Smrt Sequencing

    By Method

    • Chromatin Accessibility Sequencing
    • Chromatin Interaction Analysis
    • Dna Methylation Sequencing
    • Epigenomics
    • Histone Modification Profiling
    • Long-Range Sequencing
    • Long-Read & Long-Range Sequencing
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Ngs-Based Proteomics
    • Other Epigenomics Methods
    • Other Long-Read & Long-Range Sequencing Methods
    • Other Methods
    • Other Proteomics Methods
    • Other Single-Cell Omics
    • Other Spatial Omics
    • Pcr-Based Proteomics
    • Proteomics
    • Sequencing-Based Epigenomics
    • Single-Cell Epigenomics
    • Single-Cell Genomics
    • Single-Cell Omics
    • Single-Cell Proteomics
    • Single-Cell Transcriptomics
    • Spatial Epigenomics
    • Spatial Genomics
    • Spatial Omics
    • Spatial Proteomics
    • Spatial Transcriptomics

    By Workflow

    • Data Visualization & Analysis
    • Sample Preparation
    • Sequencing & Analysis/ Sample Characterization
    • Sequencing & Analysis/Sample Characterization

    By Application

    • Biomarker Discovery
    • Cell Biology
    • Clinical Diagnostics
    • Drug Discovery & Development
    • Immunology
    • Neurology
    • Oncology
    • Other Applications
    • Precision Medicine
    • Translational Research

    By End User

    • Academic & Research Institutes
    • Cros & Cdmos
    • Hospitals & Diagnostic/Clinical Laboratories
    • Pharmaceutical & Biotechnology Companies

    Target Audience

    • Biotech & Diagnostics Companies : Need market sizing and growth projections to develop multiomics product portfolios, establish Australian operations, and identify partnership opportunities with local healthcare institutions.
    • Healthcare Providers & Hospitals : Require insights into multiomics technology adoption trends and clinical applications to make informed investment decisions in precision medicine infrastructure and service offerings.
    • Research Institutions & Universities : Seek market data to support grant applications, justify research funding, and identify collaboration opportunities with commercial entities in Australia's growing multiomics ecosystem.
    • Investment & Venture Capital Firms : Need comprehensive market analysis and growth forecasts to evaluate investment opportunities in Australian multiomics startups and established companies with expansion potential.
    • Government & Policy Makers : Require market intelligence to inform healthcare policy, research funding allocation, and strategic initiatives supporting Australia's precision medicine and genomic healthcare development.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for Australia's multiomics market with verified CAGR projections, enabling accurate financial forecasting and investment decision-making for the 2026-2031 period.
    • Regional Competitive Intelligence : Understand Australia's positioning within Asia Pacific multiomics landscape, identifying competitive advantages and market differentiation opportunities specific to the Australian healthcare ecosystem.
    • Technology Adoption Insights : Access detailed analysis of genomic, proteomic, and metabolomic technology adoption patterns across Australian clinical and research institutions to guide product development and market entry strategies.
    • Investment & Expansion Planning : Leverage comprehensive market data to identify high-potential segments, geographic hotspots, and partnership opportunities for expanding multiomics solutions within Australia's growing healthcare sector.
    • Stakeholder-Specific Intelligence : Receive tailored insights for healthcare providers, biotech companies, investors, and researchers to support strategic planning, funding applications, and market positioning in Australia's multiomics space.

    Frequently asked questions

    What is the current size of Australia's multiomics market in 2026?

    Australia's multiomics market is valued at $47.4 million in 2026, representing a significant healthcare technology segment within the Asia Pacific region.

    What is the projected size of Australia's multiomics market by 2031?

    Australia's multiomics market is forecast to reach $83.5 million by 2031, reflecting sustained growth and increased clinical adoption.

    What is the CAGR for Australia's multiomics market from 2026 to 2031?

    Australia's multiomics market is expected to grow at a compound annual growth rate of 12.0% over the forecast period.

    Which applications are driving growth in Australia's multiomics market?

    Australia's multiomics market growth is primarily driven by precision oncology, infectious disease diagnostics, chronic disease management, and personalized medicine initiatives.

    What factors support Australia's multiomics market expansion?

    Australia's market expansion is supported by government funding for precision health, skilled scientific workforce, regulatory support, and strong academic-industry partnerships.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Multiomics Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Multiomics Market : Top-Down and Bottom-Up Approach

    Multiomics Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

    Market Definition

    The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.

    Key Stakeholders

    • Multiomics product & service providers
    • Multiomics bioinformatics/data analysis companies
    • Venture capitalists and other government funding organizations
    • Research and consulting firms
    • Hospitals and diagnostic clinics
    • Pharmaceutical and biotechnology companies
    • Academic and government research institutes
    • Life science companies

    Report Objectives

    • To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market shares and core competencies
    • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe multiomics market, by country
    • Further breakdown of the Rest of Asia Pacific multiomics market, by country

    Company Analysis

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

    Get the Full Multiomics Market Report

    Full forecast, segment splits, and company analysis for all Multiomics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status